DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for melorheostosis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMelorheostosis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for melorheostosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
LEM domain containing 3 (LEMD3) — LEMD3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5ZOJ · 2.794 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Melorheostosis is a rare condition of bone and surrounding tissues, with about 300 to 350 cases described in the literature as of 2012. A 2012 review of 313 cases found that clinical presentations range from incidental radiographic findings to deformity, resistant chronic pain, swelling, restricted joint motion, leg length discrepancy, and cervical myelopathy. Pain is the most common symptom. The condition is often associated with cutaneous and vascular changes including naevi, haemangiomas, scleroderma, lymphedema, and arteriovenous malformations. In children, presentation is more likely as limb length discrepancy, deformity, or joint contractures, which may appear before radiographic evidence of bony changes.
Treatment is symptomatic and conservative. A 2004 case report of a 14-year-old male with right upper limb hypoplasia, shortening, muscle atrophy, and thumb contracture noted that improvement in imaging techniques would allow earlier diagnosis and greater success with conservative management, and that the increased frequency of tumours necessitates long-term follow-up. A 2012 report of two surgical cases stated that involvement of a distal limb part carries more morbidity—tumefaction pain, cosmetic and psychosocial or functional problems—making conservative treatment unsatisfactory; surgical debulking or decompression provided prompt symptom relief. A 2020 case report described a 28-year-old woman with pain over the left knee and thigh, diagnosed by X-ray and MRI showing the characteristic candle-dripping-wax appearance; she was started on nonsteroidal anti-inflammatory drugs and the bisphosphonate pamidronate, which provided symptomatic betterment, and she remained symptom-free after one year of follow-up.
The 2012 review stated that therapy is individual and depends on clinical manifestation. The 2020 case report concluded that more evidence is needed to illustrate the effectiveness of medical or surgical treatments for patients with this rare diagnosis. No controlled trials, no randomised comparisons, and no data on long-term outcomes beyond single cases or small series are available. What is missing is any systematic trial design, patient stratification by subtype or severity, and funding for multi-centre studies that could move beyond anecdotal reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Kaohsiung Journal of Medical Sciences · 2012 · 18 citations · open access
Surgical treatment of melorheostosis: Report of two cases
AbstractMelorheostosis is a rare disease that usually burdens the patient with painful disability or soft tissue compromise. The treatment is usually symptomatic and conservative. Patients with severe and complicated forms of the disease may require surgery. Involvement of the distal part of a limb usually carries more morbidity, such as tumefaction pain, cosmetic and psychosocial or functional problems that render conservative treatment unsatisfactory to patients. In our series, surgical debulking or decompression of the mass effect provided prompt symptom relief.
Journal of Bone and Joint Surgery · 1950 · 18 citations
MELORHEOSTOSIS
AbstractThe case reported is characteristic of melorheostosis in that the lesions were confined to the right upper extremity. The clinical course, with gradual progression and increasing pain, is also typical. Treatment by thoracic sympathectomy gave dramatic relief from symptoms. As far as can be determined from the literature, this is the first form of treatment which has been of lasting value in this rare and painful condition.
Journal of Musculoskeletal Research · 2012 · 8 citations
MELORHEOSTOSIS: CURRENT CONCEPTS IN DIAGNOSIS AND TREATMENT — A REVIEW OF LITERATURE (313 CASES)
AbstractMelorheostosis is a rare condition of bone and surrounding tissues with different clinical presentations, ranging from clinically inapparent radiographic incidental findings to deformity, resistant chronic pain, swelling, restricted range of motion of the affected joints, leg length discrepancy or even cervical myelopathy. It is characterized by a hyperostosis of long or short bones. It is often associated with cutaneous and vascular changes like naevi, haemangiomas, scleroderma, lymphedema and arteriovenous malformations. Pain is the most common symptom of the condition. The therapy is individual and depends on the clinical manifestation. There are about 350 cases described in the literature until today. The current article presents an actual and most comprehensive review of literature to this rare condition, including 313 cases, focusing on symptomatology, diagnostic steps and the therapeutic options.
Journal of Orthopaedic Case Reports · 2020 · 8 citations · open access
Dripping Wax Bone Disease – Melorheostosis – A Rare Case Scenario
AbstractINTRODUCTION: Melorheostosis is a rare condition affecting the bones and has only been occasionally reported. We herein report a case of melorheostosis affecting left femur and tibia which was diagnosed based on clinical and radiological features and managed with bisphosphonates. CASE REPORT: A 28-year-old female patient presented with complaints of pain over left knee and thigh for the past 3 months. To evaluate the cause of pain X-ray and magnetic resonance imaging were done, which revealed characteristic candle dripping wax appearance suggestive of melorheostosis. After arriving at the diagnosis patient was started on nonsteroidal anti-inflammatory drugs and pamidronate which provided symptomatic betterment patient has now been followed up for past 1 year and is symptom free. CONCLUSION: Melorheostosis is an uncommon cause of a common symptom. Positive clinical and imaging features helped us to arrive at the diagnosis. Proper work up would help in early diagnosis and management. More evidence is needed to illustrate the effectiveness of medical or surgical treatments for patients with this rare diagnosis.
Nigerian Postgraduate Medical Journal · 2004 · 1 citations · open access
Melorheostosis of Leri: report of a case in a young African
AbstractUNLABELLED: Melorheostosis of Leri is a non-familial condition of hyperostosis of the cortical bone that usually presents unilaterally in long bones of the upper and lower limbs, but may also present in vertebra, ribs, skull and jaw. The incidence of this disease is quite rare, only about 300 cases have been reported worldwide. We present a case, which may be the first documented case in sub-Saharan Africa. CLINICAL PRESENTATION: S.K. is a 14 year old male student who presented to the hospital with an 18 month history of persistent pain in the joints of the right upper limb and a limb length discrepancy since birth which has worsened with growth. Examination revealed generalised hypoplasia of the right upper limb with shortening of the limb and atrophy of the muscles, also hypoplasia and contracture of the thumb was observed. The radiographs of the limb showed multiple areas of dense hyperostosis and scleroderma, which showed a linear distribution along the radial half of the bones. CONCLUSION: In children presentation of melorheostosis, is more likely be as limb length discrepancy, deformity or joint contractures which may be seen before radiographic evidence of any bony changes. Improvement in imaging techniques will therefore result in early diagnosis and greater success with conservative management. Also the increased frequency of tumours necessitates long-term follow up. KEYWORDS: melorheostosis, scleroderma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
